Myldamo (Modafinil)

Modafinil, the active ingredient in Myldamo, is a eugeroic (wakefulness‑promoting agent) presented as an oral dosage form for oral use. It is indicated for excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea and shift‑work disorder. GNH USA supplies Myldamo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modafinil acts on central nervous system pathways that regulate wakefulness, providing therapeutic benefit in several sleep‑related disorders.

Narcolepsy: reduces daytime sleepiness and improves alertness in patients with narcolepsy. Obstructive sleep apnea: alleviates residual daytime sleepiness in patients already receiving optimal apnea therapy. Shift‑work disorder: helps workers maintain alertness during non‑standard work hours.

Modafinil is generally well tolerated, but a range of adverse reactions has been reported.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Insomnia: difficulty initiating or maintaining sleep. - Anxiety: feelings of nervousness or tension. - Dry mouth: reduced salivation. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Severe rash or Stevens‑Johnson syndrome: requires immediate medical attention. - Psychiatric symptoms: emergence of hallucinations, mania, or depression. - Cardiovascular events: hypertension or arrhythmia. - Anaphylactic reaction: rare but potentially life‑threatening. - Hepatic injury: elevated liver enzymes or hepatitis.

Before prescribing Modafinil, clinicians should consider several safety factors.

Medical review: assess cardiovascular status and blood pressure. Pregnancy: safety not established; avoid unless benefits outweigh risks. Renal/hepatic impairment: monitor and adjust dose as needed. Psychiatric history: watch for mood changes or psychosis. Drug interactions: review concomitant medications for potential interactions. Store at ambient temperature: keep in original container, protect from moisture and heat.

Modafinil can affect the metabolism of several drugs, necessitating careful review of a patient’s medication list.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): may increase Modafinil plasma concentrations. - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce efficacy. - Monoamine oxidase inhibitors: risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce hormonal efficacy. - Antidepressants (SSRIs, SNRIs): increased risk of serotonin syndrome. - Alcohol: may enhance central nervous system depression.